IP Group invests £4m in portfolio company Microbiotica financing round.
Science and technology investor IP Group said portfolio company Microbiotica has closed a £36m financing in which it invested £4m.
IP Group
16 October 2026 07:49:16
Source: Sharecast
Microbiotica, a clinical-stage biopharma company developing a pipeline of orally-dosed, precision microbiome medicines, said the cash will support advancement of its potential treatment for ulcerative colitis into a phase two trial after initial study showed “statistically significant improvements in clinical remission versus placebo”.
Following completion of the funding round, IP Group will have an undiluted beneficial holding of 16.4% in Microbiotica, valued at £24.1m.
Microbiotica is a private, clinical-stage, biopharma company developing oral precision microbiome medicines called live biotherapeutic products (LBPs). Its lead programme, MB310, is being developed for ulcerative colitis and has demonstrated promising clinical activity and a favourable safety profile in a Phase 1b study, IP Group said in a statement on Friday.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.